AGM/EGMJun 23, 2026, 04:18 PM
UroGen Pharma Shareholders Approve ESOP Share Increase, Governance
AI Summary
UroGen Pharma Ltd. shareholders approved several key proposals at the 2026 Annual Meeting. This included an amendment to the 2017 Equity Incentive Plan, increasing authorized shares by 1,000,000, and an amendment to the Articles of Association to align shareholder proposals with Israeli law. Additionally, shareholders approved an amendment to the Non-Employee Director and Officer Compensation Policy, elected seven directors, and re-appointed PricewaterhouseCoopers LLP as the independent auditor. An advisory vote on executive compensation also passed.
Key Highlights
- Shareholders approved increasing 2017 Equity Incentive Plan shares by 1,000,000.
- Approved Amended Articles of Association with 19,306,222 votes For.
- Approved Compensation Policy Amendment with 26,089,418 votes For.
- Approved 2017 Equity Incentive Plan amendment with 25,204,644 votes For.
- Elected seven directors, including Arie Belldegrun, to the Board.
- Approved advisory vote on executive compensation with 25,125,846 votes For.
- Approved PricewaterhouseCoopers LLP as independent auditor with 36,778,509 votes For.
Price Impact
More from URGN